Berenberg Bank reissued their buy rating on shares of Shire PLC (LON:SHP) in a research note published on Tuesday morning. They currently have a GBX 5,800 ($75.71) price objective on the biopharmaceutical company’s stock.
Several other equities analysts also recently weighed in on the company. Citigroup Inc. reissued a buy rating on shares of Shire PLC in a research report on Monday, September 19th. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research report on Friday, July 22nd. HSBC downgraded Shire PLC to a hold rating and dropped their price target for the stock from GBX 5,400 ($70.49) to GBX 5,250 ($68.53) in a research report on Monday. Goldman Sachs Group Inc. restated a buy rating and set a GBX 6,300 ($82.23) price objective on shares of Shire PLC in a report on Tuesday, July 12th. Finally, BNP Paribas restated an outperform rating and set a GBX 5,700 ($74.40) price objective on shares of Shire PLC in a report on Tuesday, July 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5114.00 on Tuesday. The stock’s market capitalization is GBX 34.92 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00. The stock has a 50 day moving average price of GBX 4,984.38 and a 200-day moving average price of GBX 4,495.01.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be given a dividend of GBX 3.51 ($0.05) per share. This represents a dividend yield of 0.07%. The ex-dividend date is Thursday, September 8th.
In other Shire PLC news, insider Bohuon,Olivier bought 134 shares of the company’s stock in a transaction dated Thursday, June 30th. The shares were acquired at an average cost of GBX 4,463 ($58.26) per share, with a total value of £5,980.42 ($7,806.32).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.